Spark Therapeutics, Inc. (NASDAQ:ONCE) – Research analysts at Cantor Fitzgerald raised their FY2017 earnings per share estimates for Spark Therapeutics in a note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros now forecasts that the biotechnology company will post earnings per share of ($7.27) for the year, up from their prior estimate of ($7.84). Cantor Fitzgerald currently has a “Buy” rating on the stock. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2018 earnings at ($5.54) EPS.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the previous year, the firm posted ($1.04) EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/30/fy2017-eps-estimates-for-spark-therapeutics-inc-boosted-by-cantor-fitzgerald-once.html.

A number of other equities research analysts have also recently weighed in on ONCE. BMO Capital Markets restated an “outperform” rating and set a $89.00 price objective (up from $69.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $100.00 in a research note on Tuesday, August 8th. BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Cowen and Company restated an “outperform” rating and set a $95.00 price objective (up from $75.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $82.32.

Spark Therapeutics (NASDAQ:ONCE) opened at 81.26 on Monday. The firm has a 50-day moving average of $71.59 and a 200-day moving average of $61.05. The stock’s market cap is $2.54 billion. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $83.41.

A number of institutional investors have recently added to or reduced their stakes in ONCE. Ameritas Investment Partners Inc. boosted its position in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Spark Therapeutics during the second quarter valued at $143,000. BNP Paribas Arbitrage SA boosted its position in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. boosted its position in Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in Spark Therapeutics during the first quarter valued at $227,000. 91.01% of the stock is currently owned by institutional investors.

In other Spark Therapeutics news, Director Anand Mehra sold 6,302 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $65.00, for a total transaction of $409,630.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Barge Joseph La sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the sale, the general counsel now owns 9,567 shares in the company, valued at approximately $526,185. The disclosure for this sale can be found here. Over the last quarter, insiders sold 360,660 shares of company stock worth $25,495,351. 7.30% of the stock is owned by company insiders.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.